EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Symptom‐guided reduction of BCG dwell time: findings from the north‐ REG randomized trial

Lene Munk iD, Josephine Maria Hyldgaard, Vanaja Kumasegaram, Rikke Vilsbøl Milling, Simone Buchardt Brandt, Juan Luis Vásquez iD, Knud Fabrin, Gitte Wrist Lam, Lasse Bro, Sigurður Gudjonsson, Viveka Ströck iD, Tomas Jerlsström iD und 4 weitere

BJU International · 2026-11 · 138 (5) · 831-840

DOI: 10.1111/bju.70396 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift BJU International, online erschienen am 31.07.2026. Verfasst von Lene Munk und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Adjuvants, Immunologic, BCG Vaccine. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medac.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the impact of personalized dwell‐time (DT) reductions on symptom prevalence and systemic toxicities in patients undergoing Bacillus Calmette–Guérin (BCG) instillation for non‐muscle invasive bladder cancer (NMIBC).

Methods

Within a multinational randomized controlled trial (North‐REG Dwell Time Study [NCT04701151]), 225 patients provided daily electronic patient‐reported outcomes data during BCG induction and maintenance cycles. Participants were randomized 1:1, stratified by clinical site, sex, and concomitant carcinoma in situ, to either a standard care arm (control) or an intervention arm. Toxicity was analysed using a ‘worst‐day’ principle to capture peak symptom burden. All patients initially received a standard 120‐min DT. In the intervention group, algorithm‐guided DT reductions (to 60 or 30 min) were triggered by real‐time symptom severity, whereas the control group maintained a 120‐min DT.

Results

At baseline, 69% vs. 71% (control vs. intervention) of participants reported pre‐existing symptoms, primarily lower urinary tract symptoms such as pollakiuria and urgency. During induction, the intervention group experienced significantly lower rates of urgency at week 3 (34% vs. 47%, P = 0.04) and week 6 (32% vs. 49%, P = 0.01). Significant reductions were also observed during maintenance at week 9 for systemic symptoms (30% vs. 61%, P < 0.001) and fatigue (22% vs. 47%, P = 0.001). Total adherence to the 15‐instillation protocol was 38% in the intervention group and 40% in the control group.

Conclusion

Daily electronic patient‐reported outcomes monitoring revealed that patients with NMIBC have a high baseline symptom burden prior to BCG therapy. Symptom‐guided DT reductions may reduce local urgency and systemic toxicity and improve treatment tolerability. However, treatment completion does not seem to be affected.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adjuvants, ImmunologicBCG VaccineAgedFemaleHumansMaleMiddle AgedAdministration, IntravesicalNon-Muscle Invasive Bladder NeoplasmsPatient Reported Outcome MeasuresTime FactorsTreatment Outcome

Stichwörter der Autor:innen

BCGdrug‐related toxicitynon‐muscle‐invasive bladder cancerpatient reported outcome measuresrandomized controlled trial

Substanzen

Adjuvants, ImmunologicBCG Vaccine

Autor:innen und Institutionen

  • Department of Urology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Gynecology and Obstetrics, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Urology, Copenhagen University Hospital - Zealand University Hospital Roskilde, Roskilde, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Department of Urology, Aalborg University Hospital, Aalborg, Denmark.

ORCID-Profile: Lene Munk, Juan Luis Vásquez, Viveka Ströck, Tomas Jerlsström, Maria Skydt Lindgren, Jørgen Bjerggaard Jensen, Charlotte Graugaard-Jensen

Förderung

  • Medac

Zitieren

APA

Munk, L., Hyldgaard, J. M., Kumasegaram, V., Milling, R. V., Brandt, S. B., Vásquez, J. L., Fabrin, K., Lam, G. W., Bro, L., Gudjonsson, S., Ströck, V., Jerlsström, T., Thiel, T., Lindgren, M. S., Jensen, J. B., & Graugaard-Jensen, C. (2026). Symptom‐guided reduction of BCG dwell time: findings from the north‐ REG randomized trial. BJU International, 138(5), 831-840. https://doi.org/10.1111/bju.70396

Vancouver

Munk L, Hyldgaard JM, Kumasegaram V, Milling RV, Brandt SB, Vásquez JL, et al. Symptom‐guided reduction of BCG dwell time: findings from the north‐ REG randomized trial. BJU International. 2026;138(5):831-840. doi:10.1111/bju.70396

BibTeX
@article{Munk2026,
  author = {Munk, Lene and Hyldgaard, Josephine Maria and Kumasegaram, Vanaja and Milling, Rikke Vilsbøl and Brandt, Simone Buchardt and Vásquez, Juan Luis and Fabrin, Knud and Lam, Gitte Wrist and Bro, Lasse and Gudjonsson, Sigurður and Ströck, Viveka and Jerlsström, Tomas and Thiel, Tomas and Lindgren, Maria Skydt and Jensen, Jørgen Bjerggaard and Graugaard-Jensen, Charlotte},
  title = {Symptom‐guided reduction of BCG dwell time: findings from the north‐ REG randomized trial},
  journal = {BJU International},
  year = {2026},
  volume = {138},
  number = {5},
  pages = {831--840},
  doi = {10.1111/bju.70396}
}
Kostenlos starten →